Early/delayed cardiotoxicity; active or dormant CV disease, prior or concomitant RT to mediastinal/pericardial area, previous therapy w/ other anthracyclines or anthracenediones; severe myelosuppression; secondary leukemia; mucositis, stomatitis; tumor lysis syndrome, thrombophlebitis & thromboembolic phenomena. Inj site effects, extravasation. Assess cardiac function, hematologic profile before & during treatment. Evaluate blood uric acid, K, Ca phosphate & creatinine levels after initial treatment. Avoid use w/ live vaccine. Concomitant use of drugs w/ ability to suppress cardiac contractility or cardiotoxic drugs eg, trastuzumab. Hepatic &/or renal impairment. May affect fertility. Women of childbearing potential should use effective contraception during & at least 6.5 mth after last dose. Pregnancy. Not to be used during lactation. Infants & childn.